Previous 10 | Next 10 |
Athira Pharma ([[ATHA]] -3.7%) trades lower as it announced an underwritten public offering of 4M shares of its common stock.All of the shares in the proposed offering will be sold by Athira.Underwriters granted 30-day option to purchase up to an additional 0.6M shares of its common stoc...
BOTHELL, Wash., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc., (Nasdaq: ATHA) (“ Athira ”), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that it has comm...
Athira is a recent IPO with early but interesting data in AD. They will provide data from a potentially pivotal phase 2/3 trial in end-2022. Their HGF/MET approach is novel and deserves attention from investors. For further details see: Athira: Early Stage Alzheimer's Th...
SEATTLE, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Leen Kawas, Ph.D., President and Chief Executi...
SEATTLE, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the appointment of Kelly A. Romano to its Board of Dire...
Halvorsen's 13F portfolio value increased from $23.14B to $27.68B. The number of positions increased 71 to 86. Viking Global increased Microsoft, Mecadolibre, and CME Group while reducing Amazon.com and dropping Uber Technologies & JD.com. The top three positions are Microsoft...
Athira Pharma (ATHA) has been awarded a research grant expected to total $15M over 3 years from the National Institute on Aging of the National Institutes of Health ((NIH)) to support its Phase 2 ACT-AD trial for ATH-1017, Athira’s lead candidate being developed fo...
SEATTLE, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced it has been awarded a research grant expected to to...
Athira Pharma (ATHA) has commenced dosing in Phase 2 ACT-AD trial of ATH-1017 in patients with mild-to-moderate Alzheimer's disease.The 75-subject trial will be evaluated for improvement in cognition, global, and functional assessments comparing treatment arms to placebo.ATH-1017 is a sm...
SEATTLE, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that patient dosing has begun in ACT-AD , a Pha...
News, Short Squeeze, Breakout and More Instantly...
Reporting of Topline Results Targeted by End of Third Quarter 2024 Results to be presented in oral presentation at Clinical Trials on Alzheimer’s Disease (CTAD) on October 29, 2024, in Madrid, Spain BOTHELL, Wash., July 09, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc (N...
Company to provide overview of Phase 2/3 LIFT-AD clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease (AD); LIFT-AD topline data expected in second half of 2024 Two key opinion leaders will discuss ongoing unmet medical need and LIFT-AD’s primary endpoint...
BOTHELL, Wash., June 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it has completed the first cohort of healthy ...